Akari Therapeutics shares experienced a significant downturn on Friday, closing 13.38% lower at $0.97 per share. This substantial decline occurred despite the company announcing encouraging preclinical results for its novel antibody-drug conjugate candidate, PH1, targeting prostate cancer.
Extreme Market Volatility and Trading Activity
The trading session displayed remarkable price swings, with the stock fluctuating 23.47% between its daily low of $0.93 and peak of $1.15. Trading volume declined by 297,000 shares to just 205,000 transactions, indicating diminishing investor engagement with the security.
From a research perspective, the preclinical findings demonstrated PH1’s potential in treating tumors driven by alternative splicing factors, including androgen receptor splice variant 7 (AR-V7). This specific variant represents a critical driver in the progression of metastatic castration-resistant prostate cancer.
Corporate Financing and Strategic Shifts
Concurrent with these market movements, Akari Therapeutics completed the second tranche of its debt issuance from August 2025, securing an additional $625,000 in funding. This brings the total offering size to $3.5 million.
Should investors sell immediately? Or is it worth buying Akari Therapeutics?
The company’s strategic repositioning of its ADC program development plan toward AR-V7-driven prostate cancer represents a focused approach to an area of significant unmet medical need. Currently, no proven effective therapies exist for patients with AR-V7-driven tumors.
Technical Indicators Amid Market Pressure
Despite the recent sharp decline, both short-term and long-term moving averages continue to generate buy signals for Akari Therapeutics stock. Technical analysts have identified support levels at $0.91 and $0.87, with a breach below these thresholds potentially triggering sell signals.
The security’s exceptionally high daily volatility underscores its “very high” risk classification. Market participants anticipate the next quarterly report, expected for the fourth quarter of 2025, which may provide crucial direction for the company’s future trajectory.
Ad
Akari Therapeutics Stock: Buy or Sell?! New Akari Therapeutics Analysis from February 7 delivers the answer:
The latest Akari Therapeutics figures speak for themselves: Urgent action needed for Akari Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.
Akari Therapeutics: Buy or sell? Read more here...
